Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002267 · ClinicalTrials.gov registry record · NA
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
A NA study, sponsored by Pharmacia.
- Completed
- Registry status
- NA
- Development phase
- 750
- Enrollment target
NCT00002267: Completed NA study, sponsored by Pharmacia.
NCT00002267 is a NA study that has completed, run by Pharmacia. The registered enrollment target is 750 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002267, a NA study, has completed, sponsored by Pharmacia.
- COMPLETED
- Registry status
- NA
- Development phase
- 750 participants
- Enrollment target
Study Summary
The primary objective of this trial is to assess the safety and the relative benefit of rifabutin monotherapy in preventing or delaying the incidence of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200, as compared to placebo, and to assess if survival is prolonged in patients who receive rifabutin prophylaxis.
Interventions
- DRUG Rifabutin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Phase | NA |
What the finished NCT00002267 record still lists
NCT00002267 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which Rifabutin is the first listed.
NCT00002267 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002267 about?
NCT00002267 is a clinical study titled "Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial". The primary objective of this trial is to assess the safety and the relative benefit of rifabutin monotherapy in preventing or delaying the incidence of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200, as compared to placebo, and to assess if s...
What is the current status of trial NCT00002267?
This trial is currently completed. It is a NA study. The enrollment target is 750 participants.
What interventions are being tested in trial NCT00002267?
The interventions under investigation include: Rifabutin (DRUG).
Who is sponsoring clinical trial NCT00002267?
This trial is sponsored by Pharmacia, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002267's enrollment target sits among peer trials
750 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)